WAKEFIELD, MA, March 15, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Innovation Pharmaceuticals (OTCQB:IPIX) ("the Company"), a clinical stage biopharmaceutical company, announced today that based on positive findings new testing of Brilacidin in additional in vitro and in vivo models against hard-to-treat fungal pathogens is planned by NIH/NIAID-affiliated and other academic researchers. Brilacidin is the Company's defensin mimetic drug candidate exhibiting antimicrobial and immunomodulatory properties.
Extensive in vitro testing of Brilacidin by these research groups against multiple pathogenic human fungi has been completed. Across all pre-clinical studies conducted to date, Brilacidin has now exhibited varying degrees of inhibition against 13 of 19 "priority" fungal pathogens identified by the World Health Organization in need of novel treatments.
Summary of Research Results
Comparable to findings observed in testing by scientists at the University of Sao Paulo (USP), Brazil, Brilacidin showed potent stand-alone inhibition in multiple isolates of C. neoformans, for which few effective treatments exist. C. neoformans causes approximately 220,000 cases of cryptococcal meningitis worldwide each year and is associated with an 80 percent mortality rate. Brilacidin showed promising stand-alone inhibition as well in multiple isolates of Mucorales, Fusarium sp., C. glabrata, C. parapsilosis, C. guillermondii, Lomentospora prolificans, Scedosporium apiospermum, Blastomyces dermatitidis and Histoplasma capsulatum.
USP researchers have also shown Brilacidin to be synergistic with caspofungin in different types of fungi. Additive effects were similarly observed in Brilacidin combinations with voriconazole and geldanamycin against A. fumigatus, as well as with posaconazole against Mucorales. Separate in vitro laboratory testing evaluating Brilacidin in combination with other conventional antifungals – including caspofungin, fluconazole, posaconazole, amphotericin B and micafungin – demonstrated additive or synergistic inhibition of fungal growth.
Beyond Brilacidin's broad-spectrum ability to directly inhibit fungal pathogens, Brilacidin may favorably modulate the host response to fungal infections.
Scientific Poster Presentations
In related news, Brilacidin antifungal data was accepted for a scientific poster presentation at the 16th Annual European Conference on Fungal Genetics (ECFG16), held in Innsbruck, Austria, March 5-8, 2023, based on research conducted at USP and other academic institutions. ECFG16 is the largest European conference focusing on fungal genetics and biology.
Additional antifungal research on Brilacidin's potential to treat fungal keratitis was presented at the 2023 Gordon Research Conference on the Immunology of Fungal Infections (GRCIFI), held January 22-27, 2023, in Galveston Texas. The conference focused on advances in the mechanistic understanding of the immune response against clinically relevant fungal pathogens.
Corresponding posters for these conferences are available on the Events and Presentations section of the Company's website at the link below.
- Events and Presentations — Innovation Pharmaceuticals Inc. (ipharminc.com)
Alerts
Sign-up for Innovation Pharmaceuticals email alerts is available at:
About Innovation Pharmaceuticals
Innovation Pharmaceuticals Inc. (IPIX) is a clinical stage biopharmaceutical company developing a portfolio of innovative therapies addressing multiple areas of unmet medical need, including inflammatory diseases, cancer, and infectious diseases. The Company is also active in evaluating other potential investment opportunities that can add value and diversify its portfolio.
Forward-Looking Statements: This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 including, without limitation, statements concerning future product development plans, including with respect to specific indications; statements regarding the therapeutic potential and capabilities of the StingRay System; future regulatory developments; and any other statements which are other than statements of historical fact. These statements involve risks, uncertainties and assumptions that could cause actual results and experience to differ materially from anticipated results and expectations expressed in these forward-looking statements. The Company has in some cases identified forward-looking statements by using words such as "anticipates," "believes," "hopes," "estimates," "looks," "expects," "plans," "intends," "goal," "potential," "may," "suggest," and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements are risks related to conducting pre-clinical studies and clinical trials and seeking regulatory and licensing approvals in the United States and other jurisdictions, including without limitation that compounds and devices may not successfully complete pre-clinical or clinical testing, or be granted regulatory approval to be sold and marketed in the United States or elsewhere; prior test results may not be replicated in future studies and trials; the Company's need for, and the availability of, substantial capital in the future to fund its operations and research and development, including the amount and timing of the sale of shares of common stock under securities purchase agreements; and the Company's licensee(s) may not successfully complete pre-clinical or clinical testing and the Company will not receive milestone payments. A more complete description of these and other risk factors is included in the Company's filings with the Securities and Exchange Commission. Many of these risks, uncertainties and assumptions are beyond the Company's ability to control or predict. You should not place undue reliance on any forward-looking statements. The forward-looking statements speak only as of the information currently available to the Company on the date they are made, and the Company undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.
INVESTOR AND MEDIA CONTACTS
Innovation Pharmaceuticals Inc.
Leo Ehrlich
info@ipharminc.com
马萨诸塞州韦克菲尔德,2023年3月15日(Global Newswire)--通过临床阶段生物制药公司NewMediaWire-Innovation PharmPharmticals(OTCQB:IPIX)(“公司”),今天宣布,根据阳性结果,Brilacidin在新的体外培养和体内针对难以治疗的真菌病原体的模型是由NIH/NIAID附属的和其他学术研究人员计划的。Brilacidin是该公司的防御素模拟药物候选药物,具有抗菌和免疫调节特性。
广泛性体外培养这些研究小组已经完成了Brilacidin对多种致病人类真菌的测试。在迄今为止进行的所有临床前研究中,Brilacidin现在对世界卫生组织确定的需要新疗法的19种“优先”真菌病原体中的13种显示出不同程度的抑制作用。
研究成果摘要
与巴西圣保罗大学(USP)科学家在测试中观察到的结果相似,Brilacidin在多个分离株中显示出强大的独立抑制作用新生芽孢杆菌,对此几乎没有有效的治疗方法。新生芽孢杆菌每年导致全世界约220,000例隐球菌性脑膜炎,并与80%的死亡率有关。Brilacidin在多个分离株中也显示出良好的单独抑制作用毛霉目,镰刀菌属(Fusum sp.),光叶锦鸡儿,近视隐球虫,多产绿僵菌C.guillermondii,顶生塞多斯孢霉,皮炎芽孢杆菌和囊状组织胞浆菌。
USP的研究人员还表明,Brilacidin在不同类型的真菌中与卡泊芬净具有协同作用。在Brilacidin与伏立康唑和格尔达霉素联合使用时,也观察到类似的相加效应烟曲霉菌,以及泊沙康唑对毛霉目。各别体外培养评估Brilacidin与其他传统抗真菌药物--包括卡泊芬净、氟康唑、泊沙康唑、两性霉素B和米卡芬净--联合使用的实验室测试表明,它们具有添加剂或协同抑制真菌生长的作用。
除了Brilacidin直接抑制真菌病原体的广谱能力外,Brilacidin还可能有利地调节宿主对真菌感染的反应。
科学海报展示
在相关新闻中,Brilacidin抗真菌数据在2023年3月5日至8日在奥地利因斯布鲁克举行的第16届欧洲真菌遗传学年会(ECFG16)上被接受用于科学海报演示,该会议基于USP和其他学术机构进行的研究。ECFG16是欧洲最大的关注真菌遗传学和生物学的会议。
关于Brilacidin治疗真菌性角膜炎潜力的其他抗真菌研究于2023年1月22日至27日在德克萨斯州加尔维斯顿举行的2023年戈登真菌感染免疫学研究会议(GRCIFI)上发表。会议集中在对临床相关真菌病原体的免疫反应的机理理解方面的进展。
这些会议的相应海报可在公司网站的活动和演示部分获得,链接如下。
- 活动和演示-创新制药公司(ipharminc.com)
警报
要注册Innovation PharmPharmticals电子邮件警报,请访问:
关于创新制药公司
创新制药公司(IPIX)是一家临床阶段的生物制药公司,开发一系列创新疗法,以解决多种未得到满足的医疗需求领域,包括炎症性疾病、癌症和传染病。该公司还积极评估其他潜在的投资机会,以增加价值并使其投资组合多样化。
前瞻性陈述:本新闻稿包含根据1995年《私人证券诉讼改革法》的安全港条款作出的前瞻性陈述,包括但不限于有关未来产品开发计划的陈述,包括有关特定适应症的陈述;有关黄貂鱼系统治疗潜力和能力的陈述;未来监管发展;以及除历史事实陈述之外的任何其他陈述。这些陈述涉及风险、不确定性和假设,可能导致实际结果和经验与这些前瞻性陈述中表达的预期结果和预期大不相同。在某些情况下,公司通过使用诸如“预期”、“相信”、“希望”、“估计”、“展望”、“预期”、“计划”、“打算”、“目标”、“潜在”、“可能”、“建议”以及类似的表达方式来识别前瞻性陈述。可能导致实际结果与前瞻性陈述中表述的结果大不相同的其他因素包括与进行临床前研究和临床试验以及在美国和其他司法管辖区寻求监管和许可批准有关的风险,包括但不限于化合物和设备可能无法成功完成临床前或临床测试,或获得在美国或其他地方销售和销售的监管批准;以前的测试结果可能不会在未来的研究和试验中复制;公司未来需要和可获得的大量资本为其运营和研发提供资金,包括根据证券购买协议出售普通股的金额和时间;公司的被许可人可能无法成功完成临床前或临床测试,公司将不会收到里程碑式的付款。关于这些和其他风险因素的更完整的描述包括在该公司提交给证券交易委员会的文件中。其中许多风险、不确定性和假设超出了公司的控制或预测能力。您不应过度依赖任何前瞻性陈述。前瞻性陈述仅代表公司在发布之日目前掌握的信息,公司没有义务公开发布对任何此类前瞻性陈述的任何修订结果,除非适用法律或法规要求,否则这些修订可能反映本新闻稿发布之日之后的事件或情况,或反映意外事件的发生。
投资者和媒体联系
创新制药公司。
利奥·埃尔利希
邮箱:Info@ipharminc.com